On the back of positive Phase II data, PTC Therapeutics has agreed to acquire Censa Pharmaceuticals in a deal worth up to US$537.5 M. With the deal, PTC gains access to Censa’s Phase III-ready asset CNSA-001, an oral formulation of synthetic sepiapterin which is a precursor to tetrahydrobiopterin and a crucial cell enzyme involved in various metabolic pathways. For Censa, the deal with PTC comes just months after Retrophin declined to exercise its option to acquire it due to a strategic review.